KBC Group
PVLA

KBC Group’s Palvella Therapeutics PVLA Stock Holding History

KBC Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28K Buy
+224
New +$23.4K ﹤0.01% 1811

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KBC Group's PVLA Position: Q1 2026 in Review

KBC Group opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 224 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #1811 among its holdings.

180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • KBC Group held 224 shares of Palvella Therapeutics worth $28K as of Q1 2026.
  • Palvella Therapeutics was a new KBC Group position in Q1 2026.
  • Palvella Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1811 holding.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.